Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

导出 OA

翻译打印收藏纠错

作者： Gilles R,Dagenais ^[1] ; Leanne,Dyal ^[2] ; Jacqueline J,Bosch ^[2] ; Darryl P,Leong ^[2] ; Victor,Aboyans ^[3] ; Scott D,Berkowitz ^[4] ; Deepak L,Bhatt ^[5] ; Stuart J,Connolly ^[6] ; Keith A A,Fox ^[2] ; Eva,Muehlhofer ^[7] ; Jeffrey L,Probstfield ^[5] ; Petr,Widimsky ^[8] ; Bernhard R,Winkelmann ^[9] ; Salim,Yusuf ^[10] ; John W,Eikelboom ^[2]

作者单位： Department of Cardiology, Laval University Heart and Lung Institute, Quebec, Québec, Canada gilles.dagenais@criucpq.ulaval.ca. ^[1] Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada. ^[2] Department of Cardiology, Dupuytren University Hospital, Limoges, France. ^[3] Department of Cardiology, INSERM, U1094, Tropical Neuroepidemiology, Limoges, France. ^[4] Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA. ^[5] Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts, USA. ^[6] Department of Medicine, University of Edinburgh, Edinburgh, UK. ^[7] Department of Medicine (Cardiology), University of Washington Medical Centre, Seattle, Washington, USA. ^[8] Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic. ^[9] Kardiologische Studienpraxis und ClinPhenomics GmbH&Co, Studienzentrum Schaumainkai Frankfurt, Frankfurt, Germany. ^[10]

关键词 acute coronary syndrome clinical coronary artery disease peripheral vascular diseases pharmacology stroke